SARS-CoV-2 (COVID-19) Envelope Antibody

Contact us
ProSci
Product Code: PSI-9169
Product Group: Primary Antibodies
Supplier: ProSci
CodeSizePrice
PSI-9169-0.02mg0.02mg£150.00
Quantity:
PSI-9169-0.1mg0.1mg£449.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Virus
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
blue ice or RT
Storage:
SARS-CoV-2 (COVID-19) Envelope antibody can be stored at 4 ˚ C for three months and -20 ˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Images

1 / 4
<strong>Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Envelope in COVID-19 Patient Lung</strong><br> Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Envelope antibody (9169, 0.5 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 envelope protein was observed in macrophage of COVID-19 patient lung, but not in non-COVID-19 patient lung.
2 / 4
<strong>Figure 2 Western Blot Validation with SARS-CoV-2 Envelope Recombinant Protein</strong><br> Loading: 50 ng per lane of SARS-CoV-2 Envelope recombinant protein (92-730). Antibodies: SARS-CoV-2 (COVID-19) Envelope, 9169, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 1 μg/mL and Lane 2: 2 μg/mL
3 / 4
<strong> Figure 3 ELISA Validation with SARS-CoV-2 Envelope Recombinant Protein</strong><br> Antibodies: SARS-CoV-2 (COVID-19) Envelope Antibody, 9169. A direct ELISA was performed using SARS-CoV-2 Envelope recombinant protein (92-730) as coating antigen and the anti-SARS-CoV-2 (COVID-19) Envelope antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 1 ng/mL to 3000 ng/mL.
4 / 4
<strong> Figure 4 ELISA Validation </strong><br> Antibodies: SARS-CoV-2 (COVID-19) Envelope Antibody, 9169. A direct ELISA was performed using immunogen peptide (3531P) as coating antigen and the anti-SARS-CoV-2 (COVID-19) Envelope antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 0.3 ng/mL to 1000 ng/mL.
❮❯

<strong>Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Envelope in COVID-19 Patient Lung</strong><br> Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Envelope antibody (9169, 0.5 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 envelope protein was observed in macrophage of COVID-19 patient lung, but not in non-COVID-19 patient lung.
<strong>Figure 2 Western Blot Validation with SARS-CoV-2 Envelope Recombinant Protein</strong><br> Loading: 50 ng per lane of SARS-CoV-2 Envelope recombinant protein (92-730). Antibodies: SARS-CoV-2 (COVID-19) Envelope, 9169, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 1 μg/mL and Lane 2: 2 μg/mL
<strong> Figure 3 ELISA Validation with SARS-CoV-2 Envelope Recombinant Protein</strong><br> Antibodies: SARS-CoV-2 (COVID-19) Envelope Antibody, 9169. A direct ELISA was performed using SARS-CoV-2 Envelope recombinant protein (92-730) as coating antigen and the anti-SARS-CoV-2 (COVID-19) Envelope antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 1 ng/mL to 3000 ng/mL.
<strong> Figure 4 ELISA Validation </strong><br> Antibodies: SARS-CoV-2 (COVID-19) Envelope Antibody, 9169. A direct ELISA was performed using immunogen peptide (3531P) as coating antigen and the anti-SARS-CoV-2 (COVID-19) Envelope antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 0.3 ng/mL to 1000 ng/mL.

Documents

Further Information

Additional Names:
SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope Antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Envelope protein, E protein
Application Note:
IHC: 0.5 μg/mL; WB: 1-2 μg/mL;

Antibody validated: Immunohistochemistry in human samples. SARS-CoV-2 (COVID-19) Envelope antibody can detect 2 ng of free peptide at 1 μg/mL in ELISA. It can detect SARS-CoV-2 Envelope recombinant protein by ELISA and WB. All other applications and species not yet tested.
Background:
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019?20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The envelope protein is a small polypeptide that contains at least one ?-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic corona virus E proteins, and also viral replication (3).
Background References:
  • Gorbalenya. bioRxiv: 2020.
  • Hui et al. Int J Infect Dis. 2020;91:264-266.
  • Pervushin et al. PLoS Pathog. 2009; 5(7): e1000511.
Buffer:
SARS-CoV-2 (COVID-19) Envelope Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted reactivity based on immunogen sequence: SARS-CoV Envelope proteins: (93%)
Immunogen:
Anti-SARS-CoV-2 (COVID-19) Envelope antibody (9169) was raised against a peptide corresponding to 14 amino acids near the carboxyl terminus of SARS-CoV-2 (COVID-19) Envelope protein.

The immunogen is located within the last 50 amino acids of SARS-CoV-2 (COVID-19) Envelope protein.
NCBI Gene ID #:
43740570
NCBI Official Name:
envelope protein
NCBI Official Symbol:
E
NCBI Organism:
Wuhan seafood market pneumonia virus
Physical State:
Liquid
Protein Accession #:
QHD43418
Protein GI Number:
1791269092
Purification:
SARS-CoV-2 (COVID-19) Envelope Antibody is affinity chromatography purified via peptide column.
Research Area:
Infectious Disease,COVID-19
Swissprot #:
QHD43418
User NOte:
Optimal dilutions for each application to be determined by the researcher.